Sermorelin

Limits on what this shows

• Why no grade: PubMed was searched directly for "sermorelin mitochondria" on two separate occasions during the original review; both returned no topically relevant result (the query was algorithmically reinterpreted by PubMed's own system, and the sole result returned was an unrelated protein-AMPylation paper). A follow-up review repeated the search with the broader phrasing "growth hormone releasing hormone mitochondrial biogenesis" and this time returned a genuinely on-topic-sounding result: Rodrigue-Way A, Demers A, Ong H, Tremblay A (2007), PMID 17138655, "A growth hormone-releasing peptide promotes mitochondrial biogenesis and a fat burning-like phenotype through scavenger receptor CD36 in white adipocytes." On inspection this study uses hexarelin, a growth-hormone-releasing hexapeptide that acts at the ghrelin receptor (GHS-R1a) and, in this specific study, at the CD36 scavenger receptor, a mechanism documented elsewhere in the literature as GH-independent and distinct from the GHRH receptor that sermorelin itself activates; it was considered and explicitly excluded as not mechanistically applicable to a GHRH-receptor agonist, rather than accepted as class-level support. The same "sermorelin oxidative stress" search that supports the Oxidative stress entry above surfaced other GHRH-pathway titles referencing neurodegeneration, endoplasmic-reticulum stress, and inflammation, not mitochondrial structure or function explicitly; because their titles do not confirm mitochondrial content and their full abstracts could not be opened, they are not used here either. Six consumer/practitioner sources reviewed for the circulating-claim audit (Healthline, Testing.com, InvigorMedical, RupaHealth, FormBlends, StrivePharmacy) made no mitochondria-specific claim about sermorelin. Dual condition (no Tier B/C evidence that survives exclusion, no claim to rebut) is met on the evidence actually retrieved.

Channels tried

PubMed search-listing (2 clean attempts in the original review under "sermorelin mitochondria," both null; 1 further attempt in this follow-up review under "growth hormone releasing hormone mitochondrial biogenesis," which surfaced and required excluding the hexarelin/CD36 lead above). Crossref (1 attempt in the original review, rate-limited mid-search; 1 further attempt in this follow-up review, again rate-limited). PMC and Europe PMC (bot-blocked/rate-limited on every attempt across both reviews). 6-source consumer-claim audit (no relevant claim).

Genuine gap vs. tooling-limited

Leans more genuine after this follow-up review: three independent, clean PubMed passes across two phrasings, one of which required a considered exclusion rather than returning nothing, is a materially more thorough search than a single null attempt. The Crossref channel remains rate-limited on every attempt across both reviews, a residual, disclosed tooling gap.

Limits on what this shows

• Key negative/null findings: No study using a GHRH-receptor agonist (sermorelin's own mechanism) and measuring oxidative stress markers was located; this absence is itself the key limitation on this entry.
• At-risk subgroups: Cannot be determined from the evidence located.

Regulatory status

Not addressed in any source accessible during this review; the original FDA label could not be retrieved (see PK basis).

Population evidence

A PubMed search-listing page for "sermorelin oxidative stress" (accessed 2026-09-28) returned eight GHRH-pathway titles, none using sermorelin itself. The most directly on-topic: Nair D, Ramesh V, Li RC, Schally AV, Gozal D (2013), PMID 23815362, "Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia-induced oxidative stress and cognitive deficits in mouse," a mouse sleep-apnea model implicating GHRH signaling in oxidative stress, agonist/antagonist design not confirmed from the title. Banks WA, Morley JE, Farr SA, Price TO, Ercal N, Vidaurre I, Schally AV (2010), PMID 21135231, "Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice," an antagonist study, the opposite manipulation from sermorelin. Barabutis N, Schally AV (2008), PMID 19075233, "Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line," again an antagonist study reporting antioxidant activity from blocking the pathway sermorelin activates. Barabutis N, Siejka A, Schally AV (2011), PMID 20518847, "Growth hormone releasing hormone induces the expression of nitric oxide synthase," direction and agonist/antagonist design not confirmed from the title alone.

Mechanism

Not established for sermorelin itself. The GHRH-receptor pathway sermorelin activates appears redox-active in some tissues, but the clearest-titled findings located involve blocking that pathway (antagonism), not activating it, so a mechanism specifically predicting sermorelin's own effect cannot be stated with confidence.

Counter-evidence held on record

No source located in this review directly measured oxidative stress markers in a human or animal given sermorelin or another GHRH-receptor agonist; every class-level lead found either used an antagonist or did not specify direction. Full abstracts for all four cited titles were not accessible during this review despite repeated attempts (PubMed article pages returned no extractable text; PMC and Europe PMC were bot-blocked or rate-limited on every attempt), so this entry rests on title-level confirmation only and should be treated as a flagged mechanism-plausibility lead, not a resolved finding. Because the located evidence trends toward GHRH-pathway blockade, not activation, being associated with reduced oxidative stress and increased longevity markers in animal models, popular marketing that positions sermorelin, a pathway activator, as an antioxidant or longevity aid is not supported by anything found here and may run in the opposite direction. This is a caution flag, not a confirmed adverse effect, and no antioxidant-supplementation guidance follows from it either way.

Limits on what this shows

• Key negative/null findings: No study measuring copper status, ceruloplasmin, or copper-dependent enzyme activity in a human or animal given sermorelin or another GHRH-receptor agonist was located.
• At-risk subgroups: Not applicable; this is a context flag about the reverse relationship, not a subgroup-specific deficit.

Regulatory status

Not addressed in any source accessible during this review; the original FDA label could not be retrieved (see PK basis).

Population evidence

A PubMed search-listing page for "growth hormone releasing hormone copper metabolism" (accessed 2026-09-28) returned Yang W et al. (2011), PMID 21110139, "Effect of high dietary copper on somatostatin and growth hormone-releasing hormone levels in the hypothalami of growing pigs," an animal feeding study measuring GHRH as an outcome of dietary copper exposure. The same search returned Gajewska A et al. (2009), PMID 19375486, "Impaired growth hormone-releasing hormone neurons ultrastructure and peptide accumulation in the arcuate nucleus of mosaic mice with altered copper metabolism," an animal model of inherited copper-metabolism disease (mosaic mice) showing structural damage to GHRH-producing neurons. Both studies were confirmed at the title level via the search-listing page; full text was not opened during this review.

Mechanism

Both located studies run from copper status toward the hypothalamic GHRH system, not from GHRH or a GHRH-receptor agonist toward copper handling. No mechanism by which sermorelin, a peptide degraded by peripheral blood and tissue peptidases with no chelating or transporter-competing chemistry, would alter copper absorption, distribution, or excretion was identified in this or any other source reviewed.

Counter-evidence held on record

Per this project's interaction-direction rule, a relationship running from the nutrient toward the drug's own endogenous axis, rather than from the drug toward the nutrient, is filed as a context flag, not a depletion claim. Nothing here suggests sermorelin causes copper excess or deficiency in either direction, and no supplementation or restriction guidance follows from this entry.

Limits on what this shows

• Why no grade: Crossref was queried with "sermorelin hemoglobin anemia erythropoiesis" and returned five results, none involving sermorelin, GHRH, or a related peptide (general anemia/erythropoiesis literature only), a clean null. Direct PubMed queries for "sermorelin iron" were attempted twice in the original review and both were rejected by rate limiting (HTTP 429) before returning any result. This follow-up review reopened Vittone et al. 1997, PMID 9005976, at the abstract level via both its PubMed record and its ScienceDirect abstract page (previously the Elsevier full-text page alone had returned no extractable content at all). Both abstract sources were read directly and neither contains the words hemoglobin, hematocrit, red blood cell, red cell, anemia, or iron anywhere; the abstract instead reports GH-axis, muscle-strength/endurance, body-composition, glucose/insulin, and phosphocreatine/intracellular-pH findings only (see the ATP production entry). This confirms the abstract itself does not address iron status, though a hematologic or metabolic safety-labs table in the full text, which remains inaccessible, cannot be ruled out. No consumer source made an iron-specific claim about sermorelin.

Channels tried

Crossref (1 clean null, original review). PubMed (2 attempts in the original review, both blocked by rate limiting). Vittone 1997 abstract (opened via its PubMed record and its ScienceDirect abstract page in this follow-up review, confirmed to contain no iron/hematologic content). Vittone 1997 full text (Elsevier linkinghub redirect followed directly in this follow-up review, still returned no extractable content; Europe PMC rate-limited, HTTP 429, on every attempt; a ResearchGate search found no matching entry; Semantic Scholar rate-limited, HTTP 429). 6-source consumer-claim audit (no claim).

Genuine gap vs. tooling-limited

Less purely tooling-limited than before: the abstract of the one known drug-specific Tier A source is now confirmed read and confirmed silent on iron/hematologic parameters, which is itself informative. The gap that remains is specifically the full-text methods/results tables, which stayed inaccessible across every channel tried in this follow-up review (Elsevier, Europe PMC, ResearchGate, Semantic Scholar); this remains the single most valuable target for a future revision with different full-text access.

Limits on what this shows

• Why no grade: Crossref was queried twice with different phrasings in the original review, "sermorelin gut microbiome" and the broader "growth hormone releasing hormone GHRH gut microbiome," both clean, unblocked queries; neither returned any relevant result. Unlike this project's somatropin dossier, which located a growth-hormone-receptor-knockout mouse microbiome study at the class level, no equivalent GHRH-agonist or GHRH-pathway microbiome study could be found for sermorelin even at the class level. This follow-up review completed the PubMed pass that the original review had left rate-limited: a search-listing page for "growth hormone releasing hormone gut microbiota" returned 12 results, none involving GHRH or sermorelin and gut microbiota specifically. A further Crossref query for "sermorelin intestinal gut bacteria" also returned five results, all general gut-microbiota literature unrelated to GHRH or sermorelin. Six consumer/practitioner sources reviewed made no microbiome-related claim about sermorelin.

Channels tried

Crossref (2 clean, unblocked attempts across two phrasings in the original review, both null; 1 further clean attempt in this follow-up review, also null). PubMed (rate-limited in the original review; 1 clean attempt completed in this follow-up review, null). 6-source consumer-claim audit (no claim).

Genuine gap vs. tooling-limited

Strengthened in this follow-up review: four independent, clean, unblocked queries across two hosts and several phrasings now all return negative results, including the PubMed pass that the original review could not complete. This is now one of the best-supported genuine gaps in this dossier.

Limits on what this shows

• Key negative/null findings: The PCr/[PCr + Pi] and intracellular-pH null result above is itself the key finding for this entry: a real, drug-specific, Tier A measurement showing no effect on this energy-metabolism marker.
• At-risk subgroups: Cannot be determined; the only located study was a small (n=11), non-controlled, non-randomized, all-male, elderly cohort.

Regulatory status

Not addressed in any source accessible during this review; the original FDA label could not be retrieved (see PK basis).

Population evidence

Vittone J et al. (1997), Metabolism 46(1):89-96, PMID 9005976, DOI 10.1016/s0026-0495(97)90174-8: open-label, non-controlled study of 11 healthy men aged 64 to 76 given 2 mg GHRH(1-29), sermorelin's own active moiety, nightly for 6 weeks. Muscle bioenergetics were assessed by phosphorus-31 nuclear magnetic resonance spectroscopy during handgrip exercise, tracking the phosphocreatine-to-inorganic-phosphate ratio (PCr/[PCr + Pi]), described in the abstract as an estimate of cellular energy charge in muscle, and intracellular pH. The abstract states directly: "GHRH treatment did not alter exercise-mediated changes in PCr/[PCr + Pi] or intracellular pH." The same study found nocturnal GH release increased and two of six muscle-strength/endurance measures (upright row, shoulder press) plus abdominal-crunch endurance improved, with treatment described as altering the relationship between muscle strength and bioenergetics in a way suggesting reduced reliance on anaerobic metabolism during exercise, though ATP synthesis itself was not separately reported. Opened at the abstract level only, via the PubMed record and the ScienceDirect abstract page; the full text remains inaccessible (see Sources).

Mechanism

Not established as a depletion mechanism. Sermorelin raises endogenous GH and IGF-1, which are mechanistically plausible modulators of skeletal-muscle energy metabolism, but the one direct human measurement located shows no change in the specific high-energy phosphate marker tested.

Counter-evidence held on record

This is graded yellow rather than left ungraded because real, drug-specific Tier A evidence exists and was reviewed, not because a deficit was found; the direction is null-to-reassuring, not depletive. No claim that sermorelin depletes cellular energy stores is supported by this or any other source located in this review, and no supplementation implication follows either way. The study is small, non-controlled, and non-randomized, so its null result should not be over-read as definitive; full-text access, still unavailable, could add detail this abstract does not contain.

Limits on what this shows

• Why no grade: Crossref was queried with "sermorelin GHRH 1-29 hematocrit oxygen red blood cell" and returned five results; one was topically adjacent, an Inpharma Weekly digest (2007, DOI 10.2165/00128413-200715970-00018) noting general benefit of sermorelin in malnourished patients with advanced renal failure, but it gave no hematologic detail and was not opened beyond its title, and four results were unrelated. Direct PubMed queries for this category were blocked by rate limiting in the original review. As with Iron, this follow-up review reopened Vittone et al. 1997 at the abstract level via its PubMed record and its ScienceDirect abstract page. Neither contains hemoglobin, hematocrit, red blood cell, or oxygen-delivery language; the closest adjacent finding is that GHRH treatment altered the relationship between muscle strength and bioenergetics in a way the abstract describes as suggesting reduced need for anaerobic metabolism during exercise, a muscle-bioenergetics finding about exercise metabolism, not a hemoglobin/hematocrit/red-cell-mass measurement, so it is disclosed here but not used to support a grade for this specifically defined category. No consumer source claimed an oxygen-delivery or hematologic effect for sermorelin.

Channels tried

Crossref (1 clean attempt, one tangential non-informative lead, otherwise null, original review). PubMed (blocked on every attempt, original review). Vittone 1997 abstract (opened via its PubMed record and its ScienceDirect abstract page in this follow-up review, confirmed to contain no hemoglobin/hematocrit/oxygen-delivery content). Vittone 1997 full text (Elsevier linkinghub redirect followed directly in this follow-up review, still inaccessible; Europe PMC and Semantic Scholar both rate-limited; a ResearchGate search found no matching entry). 6-source consumer-claim audit (no claim).

Genuine gap vs. tooling-limited

Less purely tooling-limited than before, for the same reason as Iron: the abstract of the one known drug-specific Tier A source is now confirmed read and confirmed silent on hematologic and oxygen-delivery parameters specifically. The remaining gap is the full-text methods/results tables, still inaccessible across every channel tried in this follow-up review; that full text remains the first target for a future revision.